Gilead Sciences (GILD) Stock Update: Falls 0.75%, Up 10% in a Month
Technical analysis of GILD stock on November 18, 2026: price 168.98 USD, trend uptrend, RSI 59.1, support 156.04, resistance 174.48.

Why GILD is in focus today
Selected automatically from 11 NASDAQ (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.
Trend and Price Action
The structural picture remains constructive. Gilead trades above its 20-day average of $166.30 and well above its 50-day average of $156.37. The 20-day average itself rose 2.03% over five trading days, a slope that signals the short-term trend is still pointing higher. No new moving-average cross formed in the latest session; the prevailing alignment — price above the shorter average, shorter average above the longer one — is the classic setup of an intact uptrend.
Oscillators and Momentum
Momentum is where the caution lies. The 14-day Relative Strength Index reads 59.1 — neutral, with room before overbought territory at 70. Stochastic, however, is softer: %K at 39.6 sits below %D at 51.9, a bearish crossover configuration that often precedes short-term weakness. MACD tells the same story: the line at 3.897 has slipped beneath its signal at 4.347, producing a negative histogram of -0.450.
Volatility and Volume
The Average True Range over 14 days is $5.24, or 3.1% of the last price, a moderate volatility reading. In practical terms, a normal day's swing is roughly five dollars, so a 0.75% decline is well inside routine movement. The thin volume accompanying the dip reinforces that reading: sellers were not aggressive. On-balance volume, though, is falling, meaning the cumulative flow of shares has leaned toward distribution over the recent stretch. That is the one participation signal that argues against the trend's strength.Key Levels and Scenarios
Two levels frame the near term. On the upside, resistance rests at $174.48, with the three-month high of $176.58 just beyond; a decisive move through the resistance zone would confirm the uptrend and open the path suggested by the momentum reset. On the downside, the $166.30 area — where the SMA20 and Bollinger middle band converge — is the first test, followed by support at $156.04. If price slips below $166 and holds there, the trend's foundation begins to weaken; if it fails to hold $156, the uptrend is broken.Fundamental Context
The technical picture sits atop a business that is still growing. According to its SEC filing, Gilead reported quarterly revenue of $8.30 billion for the quarter ended September 30, 2026, up 6.8% from $7.77 billion a year earlier. Net income, however, fell to $2.43 billion from $3.05 billion, with diluted earnings per share of $1.94. Revenue growth paired with a lower profit line is the kind of mix that keeps investors watchful rather than euphoric. Put simply, the company is selling more but earning less per quarter — a detail that explains why a stock up more than 10% in a month can still stall.Technical Verdict: BUY
The JournalArta research verdict is BUY, scored at +66 on a −100 to +100 scale, well above the +60 threshold. Three reasons anchor the call: - Price is above its 50-day average ($156.37), and the 20-day average ($166.30) is above the 50-day — a confirmed uptrend structure. - The 20-day average is rising 2.03% over five days, showing the trend is being sustained, not flattening. - RSI at 59.1 sits in the neutral 50–70 zone, leaving room for further gains without overbought conditions; the code's signal set shows one bullish trigger — a pullback to the SMA20 within an uptrend — against zero bearish triggers. The invalidation condition: the verdict is voided if price breaks below the stop at $160.07, which would undercut the trend's structure. - Entry range: $165.06 – $168.98 - Exit targets: $182.34 (target 1) and $195.71 (target 2) - Stop loss: $160.07 - Reward/risk: 1.5 / 3.0 - Valid until: December 17, 2026 Risks to respect: the MACD histogram is negative at -0.450 and OBV is falling — momentum and participation are not yet confirming the trend, which is why the entry range sits at or below the current price rather than above it. For a non-trader, the read is simple: Gilead's long-term direction is up and the recent dip looks like a pause, but the short-term momentum gauges say the next few weeks may be choppy — and the stop at $160.07 is the line where that story would change. *This is technical analysis, not investment advice. Data reflect the November 18, 2026 session.*Summary Data GILD
| Last price | 168.98 USD |
| Change 1 day / 5 days / 1 month | -0.75% / -0.44% / 10.03% |
| Trend / MA-cross | uptrend / none |
| SMA20 / SMA50 | 166.30 / 156.37 |
| RSI (14) / Stochastic %K | 59.1 / 39.6 |
| Bollinger %B / ATR | 63% / 5.24 |
| Support / Resistance 20 days | 156.04 / 174.48 |
| Data as of | 19 November 2026 04:00 WIB |
| JournalArta research verdict (score) | Buy (+66) |
| Entry zone | 165.06 – 168.98 |
| Target 1 / 2 | 182.34 / 195.71 |
| Stop loss | 160.07 |
| Reward/risk | 1.5 / 3.0 |
Today's full Buy and Sell list for US stocks →
Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.
Track GILD stock price daily: live levels, support/resistance and our full GILD analysis history.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1Gold Silver Price November: Futures Rise Near Yearly Lows

- 2U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 3Michael Clarke Says Sandpapergate Scars Drew Steve Smith to New York

- 42027 NFL Mock Draft Puts Ohio State’s Jeremiah Smith at No. 1

- 5Brent Crude Slides 4.05% as Rising US Stockpiles Weigh on Oil

Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say
Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)













